Gordian Biotechnology

There’s a lot of discussion around how far AI can take biology. It is making therapeutic possibilities abundant, but when do we get the medicines?

The next step is a causal validation machine that distills those possibilities into the right paths to medicines.

We’re building that machine, using Mosaic Screening to scale causal validation in vivo across the entire druggable genome, disease after disease, creating a comprehensive ground-truth map of possible targets.

Revealing the entire landscape lets us map a safe path instead of wandering into the unknown wilderness.

Here’s how we do it:

In biology, some time is compressible: drug design and hypothesis generation can be sped up. Some is incompressible: biological processes need time to unfold.

As AI speeds up the surrounding work, biological timelines that cannot be compressed by AI become the main limiter to progress.

One way to get more answers per unit time despite these timelines is to causally validate many hypotheses in parallel, for example through pooled in vivo screening, like we've done for years: blog.gordian.bio/p/gordian-prog…

This means that the incompressible wait time can still massively generate evidence on hundreds of potential targets, de-risking discovery by making progress less contingent on guessing which hypothesis is correct from the get-go.

It also means that:
- AI has access to high-quality causal data from testing many targets in living diseased tissue, with their effects resolved using human ground-truth data on health VS disease
- We can map therapeutic effects across vast target spaces and multiple diseases of aging to discover the target maxima: multimorbidity drugs that treat several conditions at once.

Exciting times ahead!

Yes - robots can expand operational scale and allow us to perform more experiments and collect more of the data we’re missing.

We can also think about scale in terms of how much of the target space we can causally interrogate in a single experiment. For example, we can design pooled experiments to systematically explore a wide target space directly in living disease.

Although we can’t currently eliminate the time needed to observe disease and treatment responses, we can use that time to collect ground truth data on hundreds of interventions in parallel.

Scaling through multiplexing works: we’ve screened 1,300+ targets across six (and growing) disease areas, with osteoarthritis candidate Omen 13 now in IND-enabling studies. More in our progress report: blog.gordian.bio/p/gordian-prog…

We’re looking for an AAV CMC expert to take the first gene therapy from our cure machine toward the clinic.

Our Mosaic Screening platform tests hundreds of interventions side by side in the same diseased tissue in vivo. We've so far produced results across six disease areas. Now, we’re focused on our first AAV program, Omen 13 is a promising gene therapy candidate for the treatment of osteoarthritis that is progressing through IND enabling studies.

This program is one of the first gene therapies for a prevalent, age-related disease. As such, we’re looking for an expert who will be happy to set the bar for how an AAV for a common, age-related disease can be made.

The engagement:

You will evaluate the current state of our CMC, define our CMC strategy with our CDMO, and run the meetings which keep material on schedule and to specification.

By month 6: you will have engineering-run material ready for GLP tox, Module 3 written for pre-IND, and be in our corner as the CMC SME during FDA meetings.

You're the right person if you:
- Took an AAV program through CMC to first-in-human
Know triple-transfection HEK293 suspension processes firsthand
- Have written Module 3 for a pre-IND and IND
- Hold CDMOs to timelines and quality, and go back to the science to settle hard questions

The details: independent consulting, starting December 2026. 20-40 hours a week, remote with occasional travel.

Join us in Creating Time.

Applications reviewed on a rolling basis through October 30.

Apply here: ats.rippling.com/gordian-biotec…

Yes, we are